Regadenoson Infusion of Marginalized Donor Lungs in an EVLP System

Exclusion Criteria

• •1. Donor lung has significant pneumonia as defined by positive bacterial growth in blood culture (not related to other source of infection) or persistent purulent, un-clearable secretions on bronchoscopy OR as determined by the investigator.
• •2. Donor has aspirated gastric contents into the lung. Donor lung has significant mechanical lung injury or trauma.
• •3. Donor lung has active infections disease, such as HIV, Hepatitis B or C, HTLV or syphilis.
• •4. Donor lung must not be split and perfused as single lung on EVLP circuit.
• •1. Delta PaO2 less than 350 mmHg (measured with FiO2 set at 1.0) at two consecutive time periods at 2, 3 or 4 hours of ex Vivo perfusion.
• •2. \> 10% functional deterioration of other lung parameters during EVLP such as PVR, compliance or airway pressures.
• •1. Subject requires preoperative extracorporeal membrane oxygenation (ECMO).
• •2. Subjects who are receiving or have received within 30 days any other investigational agents.
• •3. Subjects with Burkolderia cepacia.
• •4. Subjects who have had a previous lung transplant.
• •5. Subjects who have an uncontrolled concurrent illness including, but not limited to an ongoing or active infection, uncontrolled congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements per investigator discretion.
• •6. Pregnant or breastfeeding women.